VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
Illustration for: SpaceX's $60B Cursor Deal Puts the US on Track for a Record Startup M&A Year
Value Add VC/Pulse/IPO$119.8B+ YTD

SpaceX's $60B Cursor Deal Puts the US on Track for a Record Startup M&A Year

Acquirers have spent at least $119.8 billion buying US startups so far in 2026, on pace to beat 2025's record, with SpaceX's $60 billion purchase of Cursor parent Anysphere -- the largest startup acquisition ever -- leading the charge. Biotech made up half the top-10 deals, signaling that the exit window has reopened broadly, not just for AI.

By the Numbers

$119.8B+ (YTD)
2026 M&A Spend
SpaceX–Cursor $60B
Largest Deal
Google–Wiz $32B
Prior Record
$5.15B
Capital One–Brex
$4B
Qualcomm–Modular
TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
June 25, 2026
2 min read
ShareXLinkedInEmail

THE RUNDOWN

1

A record M&A year is the liquidity relief venture has waited years for after a frozen exit market

2

The $60B Cursor deal nearly doubles the prior startup-acquisition record (Google-Wiz at $32B)

3

Biotech making up half the top deals shows the reopening extends well beyond AI

4

Newly public, cash-rich acquirers like SpaceX are using stock to go shopping at scale

TC

The VC Read · Trace's Take

Trace Cohen

After years of LPs begging for distributions, a record M&A year is the relief valve venture desperately needed -- and the most underappreciated part is that it's not just AI. Biotech being half the top-10 deals means the exit window reopened broadly, which is what real thaws look like. The deeper lesson sits in the Cursor deal: an IPO doesn't just mint liquidity, it mints acquirers, and newly public SpaceX is now spending stock the market prices by the second. Watch deal volume, not just the headline dollars -- one $60B outlier can flatter a tape that's thinner underneath.

📈 2026 IPO Tracker →💰 Funding Tracker →

Analysis

Acquirers have spent at least $119.8 billion buying US startups so far in 2026, putting the year on pace to exceed 2025's record-setting tally, according to Crunchbase News. The catalyst-in-chief is SpaceX's $60 billion acquisition of Cursor and its parent Anysphere -- the largest startup purchase ever, nearly double the previous record, which SpaceX consummated after its IPO this month using an option it took out in April.

The context reframes the deal. Before Cursor, the biggest startup acquisition on record was Google's $32 billion purchase of cloud-security firm Wiz, followed by Facebook's $19 billion WhatsApp deal in 2014. Cursor at $60 billion doesn't just break the record -- it laps it, and it demonstrates how an IPO transforms a company into an acquirer: SpaceX is spending freshly liquid public stock, the same playbook that turned Google and Meta into serial dealmakers.

“Biotech accounted for half of 2026's top-10 deals, including Eli Lilly's acquisition of Kelonia Therapeutics for up to $7 billion -- the largest biotech buyout in years.”

Crucially, the M&A surge isn't an AI-only story. Biotech accounted for half of 2026's top-10 deals, including Eli Lilly's acquisition of Kelonia Therapeutics for up to $7 billion -- the largest biotech buyout in years. Other marquee transactions include Capital One acquiring fintech Brex for $5.15 billion and Qualcomm buying AI-chip startup Modular for $4 billion. The breadth signals that the exit market has thawed across sectors, not just for the AI darlings.

For venture, this is the liquidity story that matters. After years of a frozen exit environment that left LPs starved for distributions and funds unable to recycle capital, a record M&A year -- alongside a reopening IPO window featuring SpaceX, and OpenAI and Anthropic in the wings -- finally puts cash back into the ecosystem. Strategic acquirers paying public-comparable prices for category leaders is exactly the signal founders and GPs have been waiting for.

The bear case: a record dollar figure driven by a single $60 billion outlier can mask thinner activity beneath the headline, and M&A booms can cool fast if public markets wobble or antitrust posture shifts. What to watch: whether deal volume (not just value) sustains through the second half, how regulators treat the largest transactions, and whether the newly public AI winners keep using their stock to buy.

ShareXLinkedInEmail

More on

SpaceX →Cursor →

Reported by Crunchbase News · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

IPO· Aug 9, 2026

Unitree's STAR Market IPO Subscription Opens at $9B

Illustration for: Unitree's STAR Market IPO Subscription Opens at $9B
IPO

Unitree's STAR Market IPO Subscription Opens at $9B

Unitree's Shanghai STAR Market IPO subscription formally opened at a roughly $9 billion valuation, the first profitable, scaled humanoid robotics company to go public on a major exchange.

IPO· Aug 9, 2026

Caris Leads a Wild Week for Recent IPO Stocks

Illustration for: Caris Leads a Wild Week for Recent IPO Stocks
IPO

Caris Leads a Wild Week for Recent IPO Stocks

Caris Life Sciences jumped 21.6% on a beat-and-raise quarter while BillionToOne fell 29.8% despite beating estimates, the sharpest split in the Renaissance IPO Index in weeks.

IPO· Aug 9, 2026

BillionToOne's Selloff Is a Warning for Biotech IPOs

Illustration for: BillionToOne's Selloff Is a Warning for Biotech IPOs
IPO

BillionToOne's Selloff Is a Warning for Biotech IPOs

BillionToOne beat Q2 estimates by a wide margin and still fell nearly 30% because it reiterated rather than raised guidance -- a signal about how little room newly public companies have left to disappoint.

@Trace_Cohen·t@nyvp.com